Norihiro Nishimoto

Summary

Affiliation: Osaka University
Country: Japan

Publications

  1. ncbi Inhibition of IL-6 for the treatment of inflammatory diseases
    Norihiro Nishimoto
    Laboratory of Immune Regulation, Graduate School of Frontier Biosciences, Osaka University, 1 3 Yamada oka, Suita City, Osaka, 565 0871, Japan
    Curr Opin Pharmacol 4:386-91. 2004
  2. ncbi [Anti-IL-6 receptor antibody]
    Norihiro Nishimoto
    Laboratory of Immune Regulation, Graduate School of Frontier Biosciences, Osaka University
    Nippon Rinsho 63:723-7. 2005
  3. ncbi Anti-interleukin-6 receptor antibody therapy favors adrenal androgen secretion in patients with rheumatoid arthritis: a randomized, double-blind, placebo-controlled study
    Rainer H Straub
    University Hospital Regensburg, Regensburg, Germany
    Arthritis Rheum 54:1778-85. 2006
  4. ncbi [IL-6 targetting therapy for inflammatory immune diseases]
    Norihiro Nishimoto
    Nippon Naika Gakkai Zasshi 95:1795-800. 2006
  5. ncbi The blockade of IL-6 signaling in rational drug design
    Yasuo Adachi
    Laboratory of Immune Regulation, Graduate School of Frontier Biosciences, Osaka University, Osaka, Japan
    Curr Pharm Des 14:1217-24. 2008
  6. ncbi Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease
    Norihiro Nishimoto
    Laboratory of Immune Regulation, Graduate School of Frontier Bioscience, Osaka University, Osaka, Japan
    Blood 112:3959-64. 2008
  7. ncbi Interleukin 6: from bench to bedside
    Norihiro Nishimoto
    Laboratory of Immune Regulation in the Graduate School of Frontier Biosciences, Osaka University, Suita City, Japan
    Nat Clin Pract Rheumatol 2:619-26. 2006
  8. ncbi Interleukin-6 in rheumatoid arthritis
    Norihiro Nishimoto
    Laboratory of Immune Regulation, Graduate School of Frontier Biosciences, Osaka University, Osaka, Japan
    Curr Opin Rheumatol 18:277-81. 2006
  9. ncbi Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial
    Norihiro Nishimoto
    Laboratory of Immune Regulation, Graduate School of Frontier Biosciences, Osaka University, Suita City, Osaka, Japan
    Arthritis Rheum 50:1761-9. 2004
  10. ncbi Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study
    N Nishimoto
    Laboratory of Immune Regulation, Graduate School of Frontier Biosciences, Osaka University, 1 3 Yamada oka, Suita, Osaka 565 0871, Japan
    Ann Rheum Dis 68:1580-4. 2009

Detail Information

Publications73

  1. ncbi Inhibition of IL-6 for the treatment of inflammatory diseases
    Norihiro Nishimoto
    Laboratory of Immune Regulation, Graduate School of Frontier Biosciences, Osaka University, 1 3 Yamada oka, Suita City, Osaka, 565 0871, Japan
    Curr Opin Pharmacol 4:386-91. 2004
    ..Humanized anti-IL-6 receptor antibody has been developed as a therapeutic agent for these diseases, and therapeutic benefits have been revealed in clinical studies...
  2. ncbi [Anti-IL-6 receptor antibody]
    Norihiro Nishimoto
    Laboratory of Immune Regulation, Graduate School of Frontier Biosciences, Osaka University
    Nippon Rinsho 63:723-7. 2005
  3. ncbi Anti-interleukin-6 receptor antibody therapy favors adrenal androgen secretion in patients with rheumatoid arthritis: a randomized, double-blind, placebo-controlled study
    Rainer H Straub
    University Hospital Regensburg, Regensburg, Germany
    Arthritis Rheum 54:1778-85. 2006
    ..This study investigated the influence on steroidogenesis of an interleukin-6 (IL-6)-neutralizing strategy using IL-6 receptor monoclonal antibodies (referred to as MRA)...
  4. ncbi [IL-6 targetting therapy for inflammatory immune diseases]
    Norihiro Nishimoto
    Nippon Naika Gakkai Zasshi 95:1795-800. 2006
  5. ncbi The blockade of IL-6 signaling in rational drug design
    Yasuo Adachi
    Laboratory of Immune Regulation, Graduate School of Frontier Biosciences, Osaka University, Osaka, Japan
    Curr Pharm Des 14:1217-24. 2008
    ..In this review, we discuss targeting IL-6 in a rational drug design and present the various strategies to achieve this...
  6. ncbi Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease
    Norihiro Nishimoto
    Laboratory of Immune Regulation, Graduate School of Frontier Bioscience, Osaka University, Osaka, Japan
    Blood 112:3959-64. 2008
    ..We also concluded that the increased level of free IL-6 during tocilizumab treatment closely reflects the actual endogenous IL-6 production and true disease activity...
  7. ncbi Interleukin 6: from bench to bedside
    Norihiro Nishimoto
    Laboratory of Immune Regulation in the Graduate School of Frontier Biosciences, Osaka University, Suita City, Japan
    Nat Clin Pract Rheumatol 2:619-26. 2006
    ..In this review, we discuss a paradigm of IL-6 from basic science to clinical use...
  8. ncbi Interleukin-6 in rheumatoid arthritis
    Norihiro Nishimoto
    Laboratory of Immune Regulation, Graduate School of Frontier Biosciences, Osaka University, Osaka, Japan
    Curr Opin Rheumatol 18:277-81. 2006
    ..This review addresses the pathological significance of interleukin-6 and the current status of anti-interleukin-6 therapy for rheumatoid arthritis...
  9. ncbi Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial
    Norihiro Nishimoto
    Laboratory of Immune Regulation, Graduate School of Frontier Biosciences, Osaka University, Suita City, Osaka, Japan
    Arthritis Rheum 50:1761-9. 2004
    ..This study was undertaken to evaluate the safety and efficacy of a humanized anti-IL-6 receptor antibody, MRA, in patients with RA...
  10. ncbi Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study
    N Nishimoto
    Laboratory of Immune Regulation, Graduate School of Frontier Biosciences, Osaka University, 1 3 Yamada oka, Suita, Osaka 565 0871, Japan
    Ann Rheum Dis 68:1580-4. 2009
    ..To evaluate the safety and efficacy of 5-year, long-term tocilizumab monotherapy for patients with rheumatoid arthritis...
  11. ncbi Cytokine signal regulation and autoimmune disorders
    Norihiro Nishimoto
    Laboratory of Immune Regulation, Graduate School of Frontier Biosciences, Osaka University, Japan
    Autoimmunity 38:359-67. 2005
    ..In this article, Japanese studies of cytokine signal regulation, particularly for Interleukin-6 (IL-6) in autoimmune diseases are reviewed...
  12. ncbi Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease
    Norihiro Nishimoto
    Laboratory of Immune Regulation, Graduate School of Frontier Biosciences, Osaka University, 1 3 Yamada oka, Suita, Osaka 565 0871, Japan
    Blood 106:2627-32. 2005
    ..Most adverse events were mild to moderate in severity. MRA was tolerated well and significantly alleviated chronic inflammatory symptoms and wasting in patients with MCD...
  13. ncbi Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition t
    Norihiro Nishimoto
    Laboratory of Immune Regulation, Graduate School of Frontier Biosciences, Osaka University, Osaka, Japan
    Mod Rheumatol 19:12-9. 2009
    ..All serious adverse events improved by adequate treatment. Tocilizumab monotherapy was well tolerated and provided an excellent clinical benefit in active RA patients with an inadequate response to low dose MTX...
  14. ncbi Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab
    Norihiro Nishimoto
    Laboratory of Immune Regulation, Graduate School of Frontier Biosciences, Osaka University 1 3, Yamada oka, Suita, Osaka, 565 0871, Japan
    Ann Rheum Dis 66:1162-7. 2007
    ..To evaluate the ability of tocilizumab (a humanised anti-IL-6 receptor antibody) monotherapy to inhibit progression of structural joint damage in patients with RA...
  15. ncbi Successful treatment of a patient with Takayasu arteritis using a humanized anti-interleukin-6 receptor antibody
    Norihiro Nishimoto
    Laboratory of Immune Regulation, Graduate School of Frontier Biosciences, Osaka University, Osaka, Japan
    Arthritis Rheum 58:1197-200. 2008
    ..These results indicate that IL-6R inhibition with tocilizumab might be a future treatment option for TA...
  16. ncbi Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, radiograp
    Jun Hashimoto
    Osaka University Graduate School of Medicine, Osaka, Japan
    Mod Rheumatol 21:10-5. 2011
    ..Patients at high risk for progression may benefit more from tocilizumab treatment...
  17. ncbi VEGF targeting in mesotheliomas using an interleukin-6 signal inhibitor based on adenovirus gene delivery
    Yasuo Adachi
    Laboratory of Immune Regulation, Wakayama Medical University, 105 Saito Bio Innovation Center, 7 7 20, Saito Asagi, Ibaraki City, Osaka, 567 0085, Japan
    Anticancer Res 30:1947-52. 2010
    ..In this study, we report VEGF targeting through NRI expression based on adenovirus-mediated gene delivery in mesothelioma cells...
  18. ncbi Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis
    Hideko Nakahara
    Department of Medical Science I, School of Health and Sport Sciences, Osaka University, Osaka, Japan
    Arthritis Rheum 48:1521-9. 2003
    ..IL-6 is the pivotal cytokine that induces VEGF production in synergy with IL-1beta or TNFalpha, and this may be the mechanism by which IL-6 blockade effectively suppresses VEGF production in synovial fibroblasts...
  19. ncbi Specifically modified osteopontin in rheumatoid arthritis fibroblast-like synoviocytes supports interaction with B cells and enhances production of interleukin-6
    Yasuhiro Take
    Department of Orthopaedics, Osaka University Graduate School of Medicine, and Osaka Rosai Hospital, Osaka, Japan
    Arthritis Rheum 60:3591-601. 2009
    ..The present study was undertaken to analyze the role of OPN in RA by focusing on its effects on cell-cell interactions between FLS and B lymphocytes...
  20. ncbi A combination of biochemical markers of cartilage and bone turnover, radiographic damage and body mass index to predict the progression of joint destruction in patients with rheumatoid arthritis treated with disease-modifying anti-rheumatic drugs
    Jun Hashimoto
    Osaka University Graduate School of Medicine, Osaka, Japan
    Mod Rheumatol 19:273-82. 2009
    ..High baseline U-CTX-II levels, U-PYD/DPD ratio and JSN score and a low BMI are independent predictive markers for the radiographically evident joint damage in patients with RA treated with conventional DMARDs...
  21. ncbi Effect of interleukin-6 receptor blockage on renal injury in apolipoprotein E-deficient mice
    Mari Tomiyama-Hanayama
    Department of Geriatric Medicine, Osaka University Graduate School of Medicine, Osaka, Japan
    Am J Physiol Renal Physiol 297:F679-84. 2009
    ....
  22. ncbi Serum level of oxidative stress marker is dramatically low in patients with rheumatoid arthritis treated with tocilizumab
    Makoto Hirao
    Department of Orthopaedics, Osaka University Graduate School of Medicine, Osaka, Japan
    Rheumatol Int 32:4041-5. 2012
    ..We believe that such a drastic effect would reduce the incidence of cardiovascular events and mortality in patients with rheumatoid arthritis...
  23. ncbi Abnormal networks of immune response-related molecules in bone marrow cells from patients with rheumatoid arthritis as revealed by DNA microarray analysis
    Hooi Ming Lee
    Graduate School of Frontier Biosciences, Osaka University, 1 3 Yamada oka, Suita, Osaka 565 0871, Japan
    Arthritis Res Ther 13:R89. 2011
    ..In this study, we compared differentially expressed molecules in BM cells from RA and osteoarthritis (OA) patients and analyzed abnormal regulatory networks to identify the role of BM cells in RA...
  24. ncbi Establishment of a new interleukin-6 (IL-6) receptor inhibitor applicable to the gene therapy for IL-6-dependent tumor
    Naoko Yoshio Hoshino
    Laboratory of Immune Regulation, Graduate School of Frontier Biosciences, Osaka University, 1 3 Yamadaoka, Suita City, Osaka 565 0871, Japan
    Cancer Res 67:871-5. 2007
    ..These findings indicate that NRI is a promising agent applicable to the therapeutic gene delivery approach for IL-6-driven diseases...
  25. ncbi Effects of mechanical over-loading on the properties of soleus muscle fibers, with or without damage, in wild type and mdx mice
    Masahiro Terada
    Graduate School of Frontier Biosciences, Osaka University, Toyonaka City, Osaka, Japan
    PLoS ONE 7:e34557. 2012
    ..But, it was also indicated that muscle fibers in mdx mice are susceptible to mechanical over-loading and fiber splitting and shift of myonuclei from peripheral to central region are induced...
  26. ncbi Interactions among type I and type II interferon, tumor necrosis factor, and beta-estradiol in the regulation of immune response-related gene expressions in systemic lupus erythematosus
    Hooi Ming Lee
    Laboratory of Immune Regulation, Graduate School of Frontier Biosciences, Osaka University, 1 3 Yamada oka, Suita City, Osaka 565 0871, Japan
    Arthritis Res Ther 11:R1. 2009
    ..In the present study we investigated the network of immune response-related molecules expressed in the peripheral blood of SLE patients, and the effects of cytokine interactions on the regulation of these molecules...
  27. ncbi A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus
    Yoshiya Tanaka
    First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, 1 1 Iseigaoka, Yahata Nishi, Kitakyushu 807 8555, Japan
    Mod Rheumatol 17:191-7. 2007
    ..Rituximab therapy appears to be safe for the treatment of active SLE patients and holds significant therapeutic promise, at least for the majority of patients experiencing profound B-cell depletion...
  28. ncbi Anti-interleukin-6 receptor antibody therapy in rheumatic diseases
    Hideko Nakahara
    Laboratory of Immune Regulation, Graduate School of Frontier Biosciences, Osaka University, 1-3 Yamada-oka, Suita-city, Osaka 565-0871, Japan
    Endocr Metab Immune Disord Drug Targets 6:373-81. 2006
    ..Tocilizumab treatment is generally well tolerated and safe. Therefore, tocilizumab can be a promising therapeutic agent for the rheumatic diseases in which IL-6 overproduction is pathologically involved...
  29. ncbi Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study
    Norihiro Nishimoto
    Department of Medical Science I, School of Health and Sport Sciences, Osaka University, Suita City, Japan
    J Rheumatol 30:1426-35. 2003
    ..To evaluate the safety and pharmacokinetics of multiple infusions of a humanized anti-interleukin-6 (IL-6) receptor antibody, MRA, in patients with rheumatoid arthritis (RA)...
  30. ncbi A case report of a patient with refractory adult-onset Still's disease who was successfully treated with tocilizumab over 6 years
    Hideko Nakahara
    Laboratory of Immune Regulation, Graduate School of Frontier Biosciences, Osaka University, 1 3 Yamada oka, Suita, Osaka, 565 0871, Japan
    Mod Rheumatol 19:69-72. 2009
    ..Corticosteroid and NSAIDs could be discontinued and intestinal bleeding was no more observed. Tocilizumab can be a therapeutic option for AOSD...
  31. ncbi Interleukin-6 induces both cell growth and VEGF production in malignant mesotheliomas
    Yasuo Adachi
    Laboratory of Immune Regulation, Graduate School of Frontier Biosciences, Osaka University, Osaka, Japan
    Int J Cancer 119:1303-11. 2006
    ..We concluded that IL-6-dependent growth does not occur via VEGF induction. These results suggest that treatment with anti-IL-6R antibody may constitute a potential molecular targeting therapy for MMs...
  32. ncbi Anti-interleukin 6 (IL-6) receptor antibody suppresses Castleman's disease like symptoms emerged in IL-6 transgenic mice
    Asao Katsume
    Department of Medical Science I, School of Health and Sport Sciences, Osaka University, Osaka, Japan
    Cytokine 20:304-11. 2002
    ..Furthermore, anti-IL-6R mAb could provide novel therapy for Castleman's disease and MR16-1 should be a useful tool to estimate therapeutic potential of IL-6 antagonists in a variety of murine models for human disease...
  33. ncbi Clinical studies in patients with Castleman's disease, Crohn's disease, and rheumatoid arthritis in Japan
    Norihiro Nishimoto
    Laboratory of Immune Regulation, Graduate School of Frontier Biosciences, Osaka University
    Clin Rev Allergy Immunol 28:221-30. 2005
    ....
  34. ncbi All-trans-retinoic acid inhibits the development of mesangial proliferative glomerulonephritis in interleukin-6 transgenic mice
    Yoshihito Shima
    Department of Molecular Medicine, Osaka University Graduate School of Medicine, Osaka, Japan
    Nephron Exp Nephrol 100:e54-62. 2005
    ..RT-PCR assay results showed that ATRA also reduced IL-6R, but not the glycoprotein 130 expression in mesangial cells. These findings indicate that, by blocking of the IL-6 function, ATRA may be therapeutically effective in PGN...
  35. ncbi Gene therapy for multiple myeloma
    Yasuo Adachi
    Laboratory of Immune Regulation, Graduate School of Frontier Biosciences, Osaka University, Osaka, Japan
    Curr Gene Ther 8:247-55. 2008
    ..Recently, novel therapeutic concepts for MM have been emerging. In this review, we present current progress of gene therapy related to MM treatments as well as the overview of MM treatment history...
  36. ncbi Underexpression of mitochondrial-DNA encoded ATP synthesis-related genes and DNA repair genes in systemic lupus erythematosus
    Hooi Ming Lee
    Graduate School of Frontier Biosciences, Osaka University, 1 3 Yamada oka, Suita, Osaka 565 0871, Japan
    Arthritis Res Ther 13:R63. 2011
    ..We clarify biological and functional abnormalities in SLE by comparing the gene expression profiles of SLE patients with those of healthy individuals...
  37. ncbi [Clinical benefits of anti-human IL-6 receptor antibody therapy]
    Norihiro Nishimoto
    Osaka University, Graduate School of Frontier Biosciences, Laboratory of Immune Regulation
    Clin Calcium 17:562-8. 2007
    ..Tocilizumab has been shown to ameliorate the disease activity of RA in the clinical trials. Tocilizuamb can be a new therapy based on the pathology of RA...
  38. ncbi [Anti-interleukin-6 receptor antibody therapy--from bedside to bench]
    Norihiro Nishimoto
    Laboratory of Immune Regulation, Graduate School of Frontier Biosciences, Osaka University
    Nihon Rinsho Meneki Gakkai Kaishi 29:289-94. 2006
    ..Simultaneously, we have learned new biological activities from the translational research. In this review, a study from bedside to bench is to be discussed...
  39. ncbi Uneventful splenectomy and cholecystectomy in a patient treated with anti-interleukin-6 receptor antibody therapy
    Morihiko Ishizaki
    Department of Surgery, Kitano Hospital, Tazuke Kofukai Medical Research Institute, Osaka, Japan
    Langenbecks Arch Surg 393:423-5. 2008
    ..However, in humans, the roles of IL-6 in acute phase responses after surgery remain poorly understood...
  40. ncbi Clinical value of blocking IL-6 receptor
    Toru Mima
    Laboratory of Immune Regulation, Wakayama Medical University, Wakayama City, Wakayama, Japan
    Curr Opin Rheumatol 21:224-30. 2009
    ..There is now accumulating evidence that tocilizumab is therapeutically effective for patients with RA and other inflammatory autoimmune diseases. This article reviews the clinical value of blocking IL-6R...
  41. ncbi [Inflammatory cytokines in rheumatoid arthritis]
    Miho Murakami
    Laboratory of Immune Regulation, Wakayama Medical University, Japan
    Clin Calcium 22:1737-46. 2012
    ..Biologic agents targeting these cytokines have provided beneficial outcomes, such as achievement of clinical remission, protective effects against joint destruction, and improvement in quality of life (QOL) in RA patients...
  42. ncbi Diagnostic features of mild cellulitis phlegmon in patients with rheumatoid arthritis treated with tocilizumab: a report of two cases
    Makoto Hirao
    Department of Orthopaedics, Osaka University Graduate School of Medicine, 2 2 Yamadaoka, Suita, Osaka 565 0871, Japan
    Mod Rheumatol 21:673-7. 2011
    ..Of note, the C-reactive protein (CRP) level and temperature lacked clinical utility for such detection...
  43. ncbi Cytokine networks in systemic lupus erythematosus
    Hooi Ming Lee
    Graduate School of Frontier Biosciences, Osaka University, Suita, Osaka 565 0871, Japan
    J Biomed Biotechnol 2010:676284. 2010
    ..Finally, we further discuss the influence of estrogen on these cytokine networks...
  44. ncbi Assessment of the validity of the 28-joint disease activity score using erythrocyte sedimentation rate (DAS28-ESR) as a disease activity index of rheumatoid arthritis in the efficacy evaluation of 24-week treatment with tocilizumab: subanalysis of the SAT
    Norihiro Nishimoto
    Laboratory of Immune Regulation, Wakayama Medical University, 105 Saito Bio Innovation Center, 7 7 20 Saito Asagi, Ibaraki, Osaka, 567 0085, Japan
    Mod Rheumatol 20:539-47. 2010
    ..These results confirm that the DAS28-ESR has a validity comparable to that of other methods in terms of evaluating the RA treatment efficacy of TCZ, despite its strong inflammatory marker-inhibiting effects...
  45. ncbi Early administration of IL-6RA does not prevent radiation-induced lung injury in mice
    Toshiyuki Ogata
    Department of Radiation Oncology, Osaka University Graduate School of Medicine, 2 2 Yamadaoka, Suita, Osaka, Japan
    Radiat Oncol 5:26. 2010
    ..The purpose of this study was to investigate whether anti-IL-6 monoclonal receptor antibody (IL-6RA) could ameliorate radiation-induced lung injury in mice...
  46. ncbi Masked early symptoms of pneumonia in patients with rheumatoid arthritis during tocilizumab treatment: a report of two cases
    Hiroshi Fujiwara
    Department of General Internal Medicine, Nissay Hospital, and Laboratory of Immune Regulation, Graduate School of Frontier Biosciences, Osaka University, 6 3 8 Itachibori, Nishi ku, Osaka, 550 0012, Japan
    Mod Rheumatol 19:64-8. 2009
    ..Both patients initially presented with only minimal clinical symptoms and modest elevations in serum C-reactive protein. Tocilizumab might suppress the early inflammatory symptoms of pneumonia...
  47. ncbi Characteristics of fracture and related factors in patients with rheumatoid arthritis
    Akihide Nampei
    Department of Orthopaedics, Osaka University Graduate School of Medicine, Suita, Japan
    Mod Rheumatol 18:170-6. 2008
    ..Early intervention to prevent secondary osteoporosis is recommended to maintain the quality of life in patients with rheumatoid arthritis, especially those with functional impairment or undergoing glucocorticoid therapy...
  48. ncbi A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease
    Hiroaki Ito
    Department of Molecular Medicine, Graduate School of Medicine, Osaka University, Suita
    Gastroenterology 126:989-96; discussion 947. 2004
    ..We carried out a pilot placebo-controlled study to investigate the efficacy, pharmacokinetics, and safety of MRA, a humanized monoclonal antibody to IL-6 receptor, in patients with active Crohn's disease...
  49. ncbi [Humanized anti-human IL-6 receptor antibody, tocilizumab]
    Norihiro Nishimoto
    Laboratory of Immune Regulation, Graduate School of Frontier Biosciences, Osaka University
    Nihon Rinsho 65:1218-25. 2007
    ..In this chapter, immunopharmacology and clinical utility of tocilizumab in rheumatoid arthritis is addressed...
  50. ncbi Humanized anti-interleukin 6 receptor antibody induced long-term remission in a patient with life-threatening refractory autoimmune hemolytic anemia
    Akane Kunitomi
    Department of Medicine, Kitano Hospital, The Tazuke Kofukai Medical Research Institute, Osaka, Japan
    Int J Hematol 80:246-9. 2004
    ..After 2 years of MRA treatment, the disease activity was well controlled without adverse reactions. Anti-IL-6R MoAb can be a novel and effective therapeutic agent for AIHA...
  51. ncbi Enhanced production of osteopontin in multiple myeloma: clinical and pathogenic implications
    Yukihiko Saeki
    Department of Molecular Medicine, Osaka University Graduate School of Medicine, Osaka, Japan
    Br J Haematol 123:263-70. 2003
    ..Plasma OPN levels may be a useful biomarker for assessing bone destruction in MM and distinguishing MM from MGUS or smouldering MM...
  52. ncbi [MRA for therapy of rheumatoid arthritis]
    Norihiro Nishimoto
    Laboratory of Immune Regulation, Graduate School of Frontier Biosciences, Osaka University
    Nippon Rinsho 63:538-43. 2005
  53. ncbi The paradigm of IL-6: from basic science to medicine
    Tetsuji Naka
    Department of Molecular Medicine, Osaka University Graduate School of Medicine, Japan
    Arthritis Res 4:S233-42. 2002
    ..On the basis of the findings, a new therapeutic approach to block the IL-6 signal using humanized anti-IL-6R antibody for rheumatoid arthritis, Castleman's disease, and multiple myeloma has been attempted...
  54. ncbi Sustained interleukin-6 signalling leads to the development of lymphoid organ-like structures in the lung
    Sho Goya
    Department of Molecular Medicine, Osaka University Graduate School of Medicine, Osaka, Japan
    J Pathol 200:82-7. 2003
    ..These findings imply that IL-6 signalling may play a role in the pathogenesis of lymphoproliferative disorders of the lung...
  55. ncbi Human interleukin-6 induces human herpesvirus-8 replication in a body cavity-based lymphoma cell line
    Jian Song
    Department of Medical Science I, School of Health and Sport Sciences, Osaka University, Osaka, Japan
    J Med Virol 68:404-11. 2002
    ....
  56. ncbi Myonucleus-related properties in soleus muscle fibers of mdx mice
    Masahiro Terada
    Osaka University, Japan
    Cells Tissues Organs 191:248-59. 2010
    ....
  57. ncbi Tocilizumab for the treatment of rheumatoid arthritis
    Toru Mima
    Laboratory of Immune Regulation, Graduate School of Frontier Biosciences, Osaka University, Yamada oka, Suita City, Osaka 565 0871, Japan
    Expert Rev Clin Immunol 4:165-72. 2008
    ..Studies have shown that there is no specific infection or prolongation of infection related to tocilizumab treatment. Tocilizumab is a promising therapeutic agent with statisfactory efficacy and safety for rheumatoid arthritis...
  58. ncbi The value of blocking IL-6 outside of rheumatoid arthritis: current perspective
    Miho Murakami
    Laboratory of Immune Regulation, Wakayama Medical University, Wakayama City, Wakayama, Japan
    Curr Opin Rheumatol 23:273-7. 2011
    ..This review focuses on the perspective of IL-6 blockade therapy for such IL-6-related IMIDs outside of RA...
  59. ncbi [A humanized anti-IL-6 receptor antibody(MRA) in RA therapy]
    Keisuke Hagihara
    Molecular Medicine, Graduate School of Medicine, Osaka University
    Nippon Rinsho 60:2401-7. 2002
    ..These evidence suggest that MRA has anti-arthritic effects. Clinical trials of MRA for RA patients have already started, and MRA therapy is effective as well as anti-TNF alpha and anti-IL-1 therapies...
  60. ncbi Characterization of anti-mouse interleukin-6 receptor antibody
    Makoto Okazaki
    Fuji Gotemba Research Laboratories, Chugai Pharmaceutical Co Ltd, 135 Komakado 1 chome, Gotemba shi, Shizuoka 412 8513, Japan
    Immunol Lett 84:231-40. 2002
    ..These lines of evidence demonstrate that MR16-1 is useful to investigate the physiological and pathological roles of IL-6 and sIL-6R in mice...
  61. ncbi Influences of anti-mouse interleukin-6 receptor antibody on immune responses in mice
    Masahiko Mihara
    Fuji Gotemba Research Laboratories, Chugai Pharmaceutical Co Ltd, 135, Komakado 1 Chome, Gotemba shi, Shizuoka 412 8513, Japan
    Immunol Lett 84:223-9. 2002
    ..Our results suggest that IL-6 does not always involve antibody production, although IL-6 augments antibody production, and that IL-6 is essential for the induction of Th1 cells...
  62. ncbi [Contribution of Japanese researchers to progress in the study of allergy and collagen disease in the last 100 years: IL-6 and autoimmune diseases]
    Norihiro Nishimoto
    Nippon Naika Gakkai Zasshi 91:2604-7. 2002
  63. ncbi Imaging of lesions in a murine rheumatoid arthritis model with a humanized anti-interleukin-6 receptor antibody
    Kanji Sugimoto
    Division of Tracer Kinetics, Osaka University Graduate School of Medicine
    Ann Nucl Med 19:261-6. 2005
    ..Accordingly, imaging with humanized anti-IL-6-receptor antibodies appears to be useful for detecting early pathophysiological conditions and assessing the efficacy of antibody treatment as well as the prognosis of patients with RA...
  64. ncbi [Anti-cytokine therapy for intractable hematologic diseases using monoclonal antibodies]
    Norihiro Nishimoto
    Nippon Naika Gakkai Zasshi 93:390-6. 2004
  65. ncbi Anti-interleukin 6 receptor antibody inhibits murine AA-amyloidosis
    Masahiko Mihara
    Fuji Gotemba Research Laboratories, Chugai Pharmaceutical Co Ltd, Shizuoka, Japan
    J Rheumatol 31:1132-8. 2004
    ..We examined whether anti-interleukin 6 receptor (IL-6R) antibody prevented the development of AA-amyloidosis in mouse models...
  66. ncbi Local blockade of IL-6R signaling induces lung CD4+ T cell apoptosis in a murine model of asthma via regulatory T cells
    Susetta Finotto
    Laboratory of Cellular and Molecular Immunology of the Lung, First Medical Clinic, University of Mainz, Germany
    Int Immunol 19:685-93. 2007
    ..Local targeting of IL-6R signaling could be a novel approach for inducing Th2 T cell death in allergic airways via regulatory T cells...
  67. ncbi The therapy of autoimmune diseases by anti-interleukin-6 receptor antibody
    Masahiko Mihara
    Fuji Gotemba Research Laboratories, Chugai Pharmaceutical Co Ltd, 135, Komakado 1 Chome, Shizuoka, 412 8513 Japan
    Expert Opin Biol Ther 5:683-90. 2005
    ..In all of these diseases, tocilizumab has improved the disease activity, suggesting that IL-6 plays an essential role in the pathogenesis of these diseases...
  68. ncbi [Interleukin-6 in pathogenesis of rheumatoid arthritis]
    Masahiko Mihara
    Fuji-Gotemba Research Laboratories, Chugai Pharmaceutical Co. Ltd
    Nippon Rinsho 63:158-62. 2005
  69. ncbi The IL-6R alpha chain controls lung CD4+CD25+ Treg development and function during allergic airway inflammation in vivo
    Aysefa Doganci
    Laboratory of Cellular and Molecular Immunology of the Lung, First Medical Clinic, University of Mainz, Mainz, Germany
    J Clin Invest 115:313-25. 2005
    ..Furthermore, inhibition of IL-6 signaling emerges as a novel molecular approach for the treatment of allergic asthma...
  70. ncbi TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling
    Christoph Becker
    Laboratory of Immunology, I. Medical Clinic, University of Mainz, Langenbeckstrasse 1, 55131 Mainz, Germany
    Immunity 21:491-501. 2004
    ..Taken together, our data provide novel insights into TGF-beta signaling in colorectal cancer and suggest novel therapeutic approaches for colorectal cancer based on inhibition of TGF-beta-dependent IL-6 trans-signaling...
  71. ncbi Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial
    Shumpei Yokota
    Department of Paediatrics, Yokohama City University School of Medicine, Yokohama, Japan
    Lancet 371:998-1006. 2008
    ..We investigated the efficacy and safety of tocilizumab, an anti-interleukin-6-receptor monoclonal antibody, in children with this disorder...
  72. ncbi Humanized monoclonal anti-interleukin-6 receptor antibody for treatment of intractable adult-onset Still's disease
    Masahiro Iwamoto
    Jichi Medical School, Tochigi, Japan
    Arthritis Rheum 46:3388-9. 2002
  73. ncbi Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis
    Shumpei Yokota
    Yokohama City University School of Medicine, Kanagawa, Japan
    Arthritis Rheum 52:818-25. 2005
    ....